Citation Impact
Citing Papers
Epidemiology of and Diagnostic Strategies for Toxoplasmosis
2012 Standout
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
2020
Head and neck squamous cell carcinoma
2020 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3
2015
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
2012
NF-κB signaling in inflammation
2017 Standout
The role of JAK/STAT signaling pathway and its inhibitors in diseases
2020
Rheumatoid arthritis
2018 Standout
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Rheumatoid arthritis
2016 Standout
The Binary Classification of Protein Kinases
2021
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
2012
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
2012
Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates
2018
Coordinated regulation of myeloid cells by tumours
2012 Standout
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2012
Inflammation and Colon Cancer
2010 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
2010
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Immunity, Inflammation, and Cancer
2010 Standout
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
2020
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis
2020
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
2010
Ulcerative colitis
2016 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis
2020 StandoutNobel
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
2020
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
2013
Ulcerative colitis
2020 Standout
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review
2010
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Selectivity and therapeutic inhibition of kinases: to be or not to be?
2009
Biological Therapies for Atopic Dermatitis: A Systematic Review
2021
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
2019
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Review article: novel oral‐targeted therapies in inflammatory bowel disease
2018
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma
2009
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
2013
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
2014
Abrocitinib for the treatment of atopic dermatitis
2020
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
2019
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
2019
Psoriasis Pathogenesis and Treatment
2019 Standout
Diabetes and Cancer
2010 Standout
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
2021
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
2021
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease
2018
The oral Janus kinase/spleen tyrosine kinase inhibitorASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
2019
Studies of J ak/STAT 3 expression and signalling in psoriasis identifies STAT 3‐S er727 phosphorylation as a modulator of transcriptional activity
2013
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease
2014 StandoutScienceNobel
A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
2014
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Therapeutic Targeting of the JAK /STAT Pathway
2013
Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine
2016 StandoutNobel
Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
2019
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
2020
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
2011
Works of Gary Chan being referenced
Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease
2013
Pharmacodynamic Analysis of Tofacitinib and Basiliximab in Kidney Allograft Recipients
2012
Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics
2008
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
2015
The Jak Inhibitor CP-690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells
2010
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
2018
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
2014
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
2017
Therapeutic targeting of Janus kinases
2008
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
2020
Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study
2019
The Effect of the JAK Inhibitor CP-690,550 on Peripheral Immune Parameters in Stable Kidney Allograft Patients
2009
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor
2014
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients with Crohn’s Disease: Results from a Phase 2 Open-Label 48-Week Extension Study
2017
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
2018